Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Arcutis Biotherapeutics, Inc.

Arcutis (Nasdaq: ARQT) was founded in 2016 to address significant unmet needs in medical dermatology. The company is an early commercial stage biopharmaceutical company focused on developing and commercializing best-in-class products.

Our strategy is to exploit recent innovations in inflammation and immunology to bring the best molecules to bear against validated physiologic targets known to treat dermatological diseases and disorders. 

Our management team has extensive expertise in the development and commercialization of medical dermatology products, having held key leadership roles at a number of leading dermatology companies and, collectively, has successfully developed more than 50 FDA-approved products. We believe that by leveraging our team’s unique experience and demonstrated expertise to identify, develop and commercialize best-in-class molecules against validated targets, we will be able to develop differentiated products in less time, at lower cost, and at substantially lower risk than other approaches.

Arcutis'​ combination of vision, unmet medical need, experienced management and strategic approach has attracted support from leading investors in the life sciences sector.

SLR Capital Partners

Vivo Capital

Omega Funds

OrbiMed

Pivotal bioVenture Partners

RA Capital Management

Goldman Sachs

Bain Capital

BlackRock

Frazier Healthcare Partners

HBM Healthcare Investments AG

Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT)

For #BlackHistoryMonth, we’re celebrating the legacies of Black dermatologists who paved the way in studying #skindisease in people of color. Learn about Dr. John A. Kenney, Jr., known as “the dean of Black dermatology” below. #skinofcolor

#Plaquepsoriasis is a serious #skindisease that can impact far more than your skin. Check out some common symptoms of plaque psoriasis below and find more resources from National Psoriasis Foundation at https://bit.ly/3uEnxib

#NEWS: Today, we announced that the Journal of the American Academy of Dermatology published positive results from the pivotal Phase 3 STRATUM #clinicaltrial evaluating our topical, steroid-free treatment for #seborrheicdermatitis. 

Learn more: https://bit.ly/47Tbvza 


#NEWS: Today, we announced the nationwide availability of our topical, steroid-free foam for the treatment of adults and children ages 9+ with #seborrheicdermatitis. Learn more: https://ow.ly/8azH50Qt4XA

At the annual Maui Derm meeting, we’ll share a look at our ongoing work in #atopicdermatitis. Learn more about our posters below.

NASDAQ:ARQT

Arcutis Biotherapeutics, Inc.

Last Close

10.10

26/07 20:00

Market Cap

1.14B

Beta: 0.45

Volume Today

1.46M

Avg: 993.92K

PE Ratio

−1.36

PFCF: −2.77

Filings Not Available